# Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease

> **NCT02389413** · PHASE2 · COMPLETED · sponsor: **Vivoryon Therapeutics N.V.** · enrollment: 120 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** PQ912 oral
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02389413
- **Lead sponsor:** Vivoryon Therapeutics N.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2017-06-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389413, "Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02389413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*